- Pepscan - https://www.pepscan.com -

Why epitope mapping?

Epitope mapping –  instrumental in therapeutic antibody development

Pepscan invented peptide-based epitope mapping. Building on 25 years in advanced and applied peptide chemistry, we provide accurate, clear and directly applicable epitope definitions for our client’s antibodies. Combining our scientists’ experience in immunology, biochemistry, structural and cell biology, and their expertise with our in-house developed peptide arrays and proprietary CLIPS™ technology provides us with a unique platform allowing to serve our clients in numerous purposes.

Functional understanding and selection of antibodies

Determining the binding site will establish how the epitope relates to an antibody’s functional aspects, e.g. does binding take place at a similar site as the ligand. In addition, epitope mapping can be used to select antibodies that target specific parts of a protein, e.g. for (diagnostic) assay development or therapeutic drug development.

Intellectual property and regulatory filings

Epitope mapping is a crucial and inevitable step in therapeutic antibody development. It plays a key role in IP protection and FDA/EMA approval, and therefore in protecting your company’s interests. Surprisingly, though, less than 10% of antibody patents filed mention epitope mapping. In the majority of 2019 European patents that did mention epitope mapping, Pepscan was the company of choice.

Our epitope mapping platform supports not only your Intellectual Property claims but also builds a functional understanding that allows selection of the best candidate antibodies with preferred specificity by:

Most of these aspects can be mapped with either our linear [1], conformational [2] or discontinuous [3] mapping, while sometimes a more in-depth approach is needed to characterize single amino acid properties using fine mapping [4].